A detailed history of Los Angeles Capital Management LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 13,580 shares of VIR stock, worth $117,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,580
Previous 13,331 1.87%
Holding current value
$117,331
Previous $118,000 14.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$7.26 - $10.7 $1,807 - $2,664
249 Added 1.87%
13,580 $101,000
Q2 2024

Aug 05, 2024

BUY
$7.63 - $12.66 $101,715 - $168,770
13,331 New
13,331 $118,000
Q1 2023

May 04, 2023

SELL
$22.26 - $30.85 $883,009 - $1.22 Million
-39,668 Reduced 63.04%
23,257 $541,000
Q4 2022

Feb 06, 2023

SELL
$19.96 - $28.22 $18,942 - $26,780
-949 Reduced 1.49%
62,925 $1.59 Million
Q3 2022

Nov 02, 2022

BUY
$18.26 - $31.1 $884,039 - $1.51 Million
48,414 Added 313.16%
63,874 $1.23 Million
Q2 2022

Aug 05, 2022

SELL
$19.08 - $26.7 $471,066 - $659,196
-24,689 Reduced 61.49%
15,460 $394,000
Q1 2022

May 06, 2022

BUY
$21.19 - $40.01 $474,592 - $896,103
22,397 Added 126.17%
40,149 $1.03 Million
Q4 2021

Feb 03, 2022

BUY
$30.97 - $54.03 $203,813 - $355,571
6,581 Added 58.91%
17,752 $743,000
Q3 2021

Nov 08, 2021

BUY
$34.9 - $54.54 $349 - $545
10 Added 0.09%
11,171 $486,000
Q2 2021

Aug 05, 2021

SELL
$38.75 - $51.0 $23,250 - $30,600
-600 Reduced 5.1%
11,161 $528,000
Q1 2021

May 05, 2021

SELL
$26.34 - $83.07 $351,718 - $1.11 Million
-13,353 Reduced 53.17%
11,761 $602,000
Q4 2020

Feb 04, 2021

BUY
$25.51 - $43.38 $307,038 - $522,121
12,036 Added 92.03%
25,114 $673,000
Q3 2020

Nov 02, 2020

BUY
$28.28 - $53.6 $369,845 - $700,980
13,078 New
13,078 $449,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.15B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.